JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) - Total Liabilities
Based on the latest financial reports, JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) has total liabilities worth Rs8.09 Billion INR (≈ $87.54 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore JBCHEPHARM long-term investment intensity to see how much of total assets are deployed in long-term investments.
JB Chemicals & Pharmaceuticals Limited - Total Liabilities Trend (2005–2026)
This chart illustrates how JB Chemicals & Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see JB Chemicals & Pharmaceuticals Limited asset portfolio.
JB Chemicals & Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of JB Chemicals & Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chengdu Xuguang Electronics Co Ltd
SHG:600353
|
China | CN¥1.52 Billion |
|
Zhejiang Lante Optics Co Ltd
SHG:688127
|
China | CN¥810.68 Million |
|
De Grey Mining Ltd
AU:DEG
|
Australia | AU$33.89 Million |
|
State Grid Yingda Co Ltd
SHG:600517
|
China | CN¥20.91 Billion |
|
Chongyi Zhangyuan Tungsten Co Ltd
SHE:002378
|
China | CN¥6.45 Billion |
|
Jiangsu Xinquan Automotive Trim Co Ltd
SHG:603179
|
China | CN¥11.73 Billion |
|
Regis Resources Ltd
AU:RRL
|
Australia | AU$661.86 Million |
|
Xinfengming Group Co Ltd
SHG:603225
|
China | CN¥46.00 Billion |
Liability Composition Analysis (2005–2026)
This chart breaks down JB Chemicals & Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See JBCHEPHARM equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how JB Chemicals & Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for JB Chemicals & Pharmaceuticals Limited (2005–2026)
The table below shows the annual total liabilities of JB Chemicals & Pharmaceuticals Limited from 2005 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs8.09 Billion ≈ $87.54 Million |
-3.69% |
| 2025-03-31 | Rs8.40 Billion ≈ $90.89 Million |
-21.51% |
| 2024-03-31 | Rs10.71 Billion ≈ $115.80 Million |
-0.25% |
| 2023-03-31 | Rs10.74 Billion ≈ $116.10 Million |
+129.00% |
| 2022-03-31 | Rs4.69 Billion ≈ $50.70 Million |
+10.39% |
| 2021-03-31 | Rs4.25 Billion ≈ $45.93 Million |
+13.08% |
| 2020-03-31 | Rs3.76 Billion ≈ $40.62 Million |
+21.91% |
| 2019-03-31 | Rs3.08 Billion ≈ $33.32 Million |
-3.89% |
| 2018-03-31 | Rs3.21 Billion ≈ $34.67 Million |
+4.01% |
| 2017-03-31 | Rs3.08 Billion ≈ $33.33 Million |
-33.30% |
| 2016-03-31 | Rs4.62 Billion ≈ $49.97 Million |
-6.16% |
| 2015-03-31 | Rs4.92 Billion ≈ $53.25 Million |
+59.76% |
| 2014-03-31 | Rs3.08 Billion ≈ $33.33 Million |
+10.10% |
| 2013-03-31 | Rs2.80 Billion ≈ $30.27 Million |
+22.86% |
| 2012-03-31 | Rs2.28 Billion ≈ $24.64 Million |
-25.98% |
| 2011-03-31 | Rs3.08 Billion ≈ $33.29 Million |
+14.50% |
| 2010-03-31 | Rs2.69 Billion ≈ $29.08 Million |
-3.09% |
| 2009-03-31 | Rs2.77 Billion ≈ $30.00 Million |
-3.77% |
| 2008-03-31 | Rs2.88 Billion ≈ $31.18 Million |
-1.89% |
| 2007-03-31 | Rs2.94 Billion ≈ $31.78 Million |
+68.00% |
| 2006-03-31 | Rs1.75 Billion ≈ $18.91 Million |
+37.57% |
| 2005-03-31 | Rs1.27 Billion ≈ $13.75 Million |
-- |
About JB Chemicals & Pharmaceuticals Limited
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dos… Read more